SLGC

SomaLogic, Inc. [SLGC] Stock Forecast

Q: What is SomaLogic, Inc. stock symbol ?

SomaLogic, Inc. is a US stock, located in Boulder of Co and trading under the symbol SLGC

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SLGC Stock Summary

Earnings have grown 19.65% per last year.

EPS has been increasing for the past 3 quarters (Quarter statements)

SLGC has more than 3 years of cash runway (47 months)

Earnings are expected to fall -100% next year

Profit margins (-1.6%) are lower than the previous year (-1.12%)

In the News

SLGC Financial details

Company Rating

Neutral

Market Cap

396.23M

Income

-130.38M

Revenue

81.72M

Book val./share

2.66

Cash/share

2.43

Dividend

Dividend %

Employees

451

Optionable

Shortable

Yes

Earnings

26 Mar 2024

P/E

-3.01

Forward P/E

PEG

-3.16

P/S

4.85

P/B

0.79

P/C

0.86

P/FCF

-3.25

Quick Ratio

17.08

Current Ratio

17.79

Debt / Equity

0.03

LT Debt / Equity

0.01

EPS (TTM)

-0.69

EPS next Y

EPS next Q

EPS this Y

-6.35%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

7.72%

EPS Q/Q

-7.69%

SMA20

-33.33%

SMA50

SMA100

Inst Own

55.55%

Inst Trans

0.83%

ROA

-23%

ROE

-25%

ROC

-0.29%

Gross Margin

41%

Oper. Margin

-188%

Profit Margin

-160%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.73-3.79

52W High

-30%

52W Low

+110%

RSI

Rel Volume

14.95

Avg Volume

2.27M

Volume

33.91M

Perf Week

-21.05%

Perf Month

-22.51%

Perf Quarter

Perf Half Y

-2.78%

Beta

1.639

Volatility

0.16%, 0.24%

Prev Close

Price

2.1

Change

-2.78%

SLGC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0.31	0.6	0.53
Net income per share	0	-0.39	-0.63	-0.59
Operating cash flow per share	0	-0.16	-0.27	-0.55
Free cash flow per share	0	-0.16	-0.32	-0.58
Cash per share	0	1.13	4.8	2.93
Book value per share	0	1.03	4.46	3.06
Tangible book value per share	0	1.03	4.46	2.91
Share holders equity per share	0	1.03	4.46	3.06
Interest debt per share	0	0.3	0.01	-0.58
Market cap	0	2.51B	1.6B	461.82M
Enterprise value	-14.06M	2.38B	1.16B	42.47M
P/E ratio	0	-35.12	-18.5	-4.23
Price to sales ratio	0	44.84	19.56	4.73
POCF ratio	0	-88.43	-43.18	-4.59
PFCF ratio	0	-84.96	-36.53	-4.36
P/B Ratio	0	13.48	2.61	0.82
PTB ratio	0	13.48	2.61	0.82
EV to sales	-0.44	42.54	14.18	0.43
Enterprise value over EBITDA	0.29	-75.95	-15.83	-0.25
EV to operating cash flow	0.28	-83.9	-31.3	-0.42
EV to free cash flow	0.27	-80.61	-26.48	-0.4
Earnings yield	0	-0.03	-0.05	-0.24
Free cash flow yield	0	-0.01	-0.03	-0.23
Debt to equity	1.79	0.2	0	0
Debt to assets	0.51	0.15	0	0
Net debt to EBITDA	0.29	4.1	6.01	2.5
Current ratio	6.71	13.03	23.61	13.42
Interest coverage	0	-1.87	-55.37	1.61
Income quality	0.89	0.53	0.42	0.92
Dividend Yield	0	0	0	0
Payout ratio	0	0	0	0
Sales general and administrative to revenue	1.04	0.66	0.95	1.57
Research and developement to revenue	1.01	0.55	0.53	0.75
Intangibles to total assets	0	0	0	0.04
Capex to operating cash flow	0.01	0.04	0.18	0.05
Capex to revenue	-0.02	-0.02	-0.08	-0.05
Capex to depreciation	-0.22	-0.41	-2.62	-1.14
Stock based compensation to revenue	0.41	0.27	0.35	0.45
Graham number	0	3.02	7.95	6.39
ROIC	-0.89	-0.21	-0.12	-0.31
Return on tangible assets	-0.8	-0.29	-0.12	-0.18
Graham Net	0	0.91	4.24	2.58
Working capital	50.86M	214.18M	662.27M	538.37M
Tangible asset value	20.42M	185.92M	612.02M	535.46M
Net current asset value	8.93M	175.6M	597.47M	496.89M
Invested capital	1.79	0.2	0	0
Average receivables	0	10.83M	17.26M	17.04M
Average payables	0	5.04M	11.08M	15.94M
Average inventory	0	7.73M	9.12M	12.56M
Days sales outstanding	47.66	113.96	76.35	63.56
Days payables outstanding	22.17	114.02	164.58	141.36
Days of inventory on hand	61.89	113.31	122.31	116.97
Receivables turnover	7.66	3.2	4.78	5.74
Payables turnover	16.46	3.2	2.22	2.58
Inventory turnover	5.9	3.22	2.98	3.12
ROE	-2.79	-0.38	-0.14	-0.19
Capex per share	0	-0.01	-0.05	-0.03

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.23	0.1	0.11	0.11	0.12
Net income per share	-0.18	-0.26	-0.18	-0.13	-0.12
Operating cash flow per share	-0.19	-0.19	-0.23	-0.14	-0.11
Free cash flow per share	-0.21	-0.15	-0.24	-0.15	-0.12
Cash per share	3.07	2.9	2.68	2.54	2.43
Book value per share	3.27	3.02	2.87	2.76	2.66
Tangible book value per share	3.12	2.87	2.72	2.61	2.51
Share holders equity per share	3.27	3.02	2.87	2.76	2.66
Interest debt per share	-0.04	-0.3	-0.03	0.06	0.07
Market cap	534.78M	467.65M	475.64M	431.37M	447.1M
Enterprise value	154.41M	48.29M	37.13M	76.83M	144.29M
P/E ratio	-4.06	-2.37	-3.48	-4.35	-5.04
Price to sales ratio	12.82	24.84	23.34	21.08	20.28
POCF ratio	-15.28	-13.47	-11.05	-16.44	-20.93
PFCF ratio	-13.57	-16.67	-10.74	-15.76	-20.18
P/B Ratio	0.89	0.83	0.89	0.84	0.9
PTB ratio	0.89	0.83	0.89	0.84	0.9
EV to sales	3.7	2.56	1.82	3.75	6.54
Enterprise value over EBITDA	-4.17	-0.97	-0.9	-2.58	-7.94
EV to operating cash flow	-4.41	-1.39	-0.86	-2.93	-6.75
EV to free cash flow	-3.92	-1.72	-0.84	-2.81	-6.51
Earnings yield	-0.06	-0.11	-0.07	-0.06	-0.05
Free cash flow yield	-0.07	-0.06	-0.09	-0.06	-0.05
Debt to equity	0	0	0	0.02	0.03
Debt to assets	0	0	0	0.02	0.02
Net debt to EBITDA	10.27	8.41	10.63	11.92	16.65
Current ratio	14.56	13.42	14.07	16.39	17.79
Interest coverage	5.76	0.93	6.71	0	0
Income quality	1.06	0.71	1.26	1.06	0.96
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	1.82	0	0	0
Research and developement to revenue	0.47	1.2	0.69	0.53	0.47
Intangibles to total assets	0.04	0.04	0.04	0.05	0.05
Capex to operating cash flow	0.13	-0.19	0.03	0.04	0.04
Capex to revenue	-0.11	0.35	-0.06	-0.06	-0.04
Capex to depreciation	-3.76	3.97	-0.72	-0.6	-0.42
Stock based compensation to revenue	0.41	0.46	0.35	0.21	0.18
Graham number	3.62	4.24	3.44	2.87	2.66
ROIC	-0.07	-0.1	-0.08	-0.06	-0.06
Return on tangible assets	-0.05	-0.08	-0.06	-0.04	-0.04
Graham Net	2.76	2.55	2.4	2.29	2.18
Working capital	578.59M	538.37M	508.18M	484.76M	466.32M
Tangible asset value	575.51M	535.46M	508.21M	488.05M	469.64M
Net current asset value	535.69M	496.89M	468.12M	445.67M	425.8M
Invested capital	0	0	0	0.02	0.03
Average receivables	19.37M	21.03M	21.3M	23.67M	21.24M
Average payables	19.69M	18.54M	19.74M	17.88M	12.27M
Average inventory	19.63M	16.2M	14.47M	15.09M	14.5M
Days sales outstanding	54.05	81.29	112.99	95.64	84.62
Days payables outstanding	156.52	116.58	165.71	105.33	88.63
Days of inventory on hand	142.67	96.47	109.99	121.8	107.4
Receivables turnover	1.67	1.11	0.8	0.94	1.06
Payables turnover	0.58	0.77	0.54	0.85	1.02
Inventory turnover	0.63	0.93	0.82	0.74	0.84
ROE	-0.05	-0.09	-0.06	-0.05	-0.04
Capex per share	-0.02	0.04	-0.01	-0.01	0

SLGC Frequently Asked Questions

What is SomaLogic, Inc. stock symbol ?

SomaLogic, Inc. is a US stock , located in Boulder of Co and trading under the symbol SLGC

What is SomaLogic, Inc. stock quote today ?

SomaLogic, Inc. stock price is $2.1 today.

Is SomaLogic, Inc. stock public?

Yes, SomaLogic, Inc. is a publicly traded company.

Something similar

Top by Market Cap

AAPL

Company Profile

Volume Average 2.27M
Market Capitalization 396.23M
Employee 451
CEO Dr. Stephen A. Williams BS, MB, Ph.D.
Headquarters Boulder,CO,US
IPO Date 2021-04-23
Website https://www.somalogic.com

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.